4 recruiting, 2 not yet recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Not yet recruiting 2 |
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Multiple Myeloma Refractory: new trials by email Literature Review of Multiple Myeloma Refractory trials Research Report on Multiple Myeloma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma VV169 - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Vyriad, Inc. | 40 | 2026-09-08 | 2026-09-21 |
| Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) Allogeneic, off-the-shelf CAR-T cell injection targeting BCMA and GPRC5D - Multiple Myeloma Refractory, Multiple Myeloma Progression | Phase 1 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 16 | 2026-06-01 | 2026-06-03 |
| Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma Liposomal Curcumin (LipoCurc) - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 1 | Recruiting | University Health Network, Toronto | 20 | 2026-02-27 | 2026-06-12 |
| Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. Autologous BCMA-targeting CAR T cells - Multiple Myeloma in Relapse, Multiple Myeloma Refractory | Phase 1 / Phase 2 | Not yet recruiting | Hebei Senlang Biotechnology Inc., Ltd. | 24 | 2026-02-01 | 2026-02-19 |
| Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients HuL001, Lenalidomide/Dexamethasone - Multiple Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | HuniLife Biotechnology, Inc. | 21 | 2025-08-18 | 2026-09-18 |
| Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma anti BCMA CAR-T cells - Multiple Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 30 | 2025-02-01 | 2026-10-16 |
Multiple Myeloma (3)
Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Vascular Diseases (3)
Dexamethasone (1) · Lenalidomide (1)
Hebei Senlang Biotechnology Inc., Ltd. (1) · HuniLife Biotechnology, Inc. (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1) · University Health Network, Toronto (1) · Vyriad, Inc. (1) · Zhongshan Hospital (Xiamen), Fudan University (1)
Belarus (1) · Canada (1) · Taiwan (1) · United States (1)
Jin Lu (1) · Maisie Huang, PhD (1) · Mikhail Uss, MD (1)